You are not connected
15
1
GeneQuine Biotherapeutics GmbH
Company
|
Germany
Primary tabs
About your organization
GeneQuine develops next generation gene therapy for musculoskeletal diseases with a potentially disease-modifying lead candidate for osteoarthritis.
In 2017, GeneQuine sold its (then-) lead program for osteoarthritis to Flexion Therapeutics Inc. for up to $64 million.
GeneQuine is currently raising a series A of €16 million to take its second gene therapy drug candidate for osteoarthritis to the clinic, to start a development program for degenerative disc disease, and to expand its lab.
Network (0)
There are no organizations in the network.